Rituximab done: what&#039;s next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis

Browse by...

Deposit

Highlights

More informations

Title		Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis
Authors		Walker, Ulrich A Jaeger, Veronika K Chatzidionysiou, Katerina Hetland, Merete L Hauge, Ellen-Margrethe Pavelka, Karel Nordström, Dan C Canhão, Helena Tomšič, Matija van Vollenhoven, Ronald Gabay, Cem show all authors [1 - 11]
Published in		Rheumatology. 2016, vol. 55, no. 2, p. 230-236
Abstract		To compare the effectiveness of biologics after rituximab (RTX) treatment in RA.
Keywords		Antirheumatic Agents/therapeutic use — Arthritis, Rheumatoid/drug therapy — Disease Progression — Europe — Female — Follow-Up Studies — Humans — Male — Middle Aged — Prospective Studies — Registries — Rituximab/therapeutic use — Time Factors — Treatment Outcome
Identifiers		DOI: 10.1093/rheumatology/kev297 PMID: 26316581
Full text		Article (Published version) (198 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine interne
Research group		Mécanisme de l'inflammation articulaire (44)
Citation (ISO format)		WALKER, Ulrich A et al. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. In: Rheumatology, 2016, vol. 55, n° 2, p. 230-236. https://archive-ouverte.unige.ch/unige:86816